Table 1 Baseline Characteristics
| Â | PMR (n = 28) | SCS (n = 28) |
|---|---|---|
Mean age in years (SD) | 62.3 (9.7) | 64.4 (7.5) |
Previous revascularisation | 28 (100%) | 28 (100%) |
Baseline medication | Â | Â |
Beta-blockers | 22 (79%) | 23 (82%) |
Calcium channel blockers | 22 (79%) | 23 (82%) |
Aspirin | 24 (86%) | 26 (93%) |
Nicorandil | 26 (93%) | 24 (86%) |
Long-acting nitrates | 23 (82%) | 21 (75%) |
ACE -inhibitors | 13 (46%) | 14 (50%) |
Follow-up medication | Â | Â |
Beta-blockers | 20 (71%) | 24 (86%) |
Calcium channel blockers | 20 (71%) | 23 (82%) |
Aspirin | 23 (82%) | 23 (82%) |
Nicorandil | 25 (89%) | 22 (79%) |
Long-acting nitrates | 23 (82%) | 22 (79%) |
ACE – inhibitors | 13 (46%) | 15 (54 %) |